Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium (Nasdaq: COLL) will acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with up to $135 million in contingent milestone payments. The deal is expected to close in Q2 2026, be immediately accretive to adjusted EBITDA, and deliver pro forma AZSTARYS net revenue of over $50 million in H2 2026.
Funding combines cash on hand and a $300 million delayed draw term loan; AZSTARYS is supported by patents into December 2037. Closing is subject to customary regulatory and HSR approvals.
Collegium (Nasdaq: COLL) will present two real-world data posters at PainConnect 2026, AAPM's annual meeting in Salt Lake City, March 5-8, 2026. The posters, presented March 6 on TV 1 at The Grand America Hotel, analyze buprenorphine real-world use and urine drug testing.
Presentations by Jody L. Green, PhD, highlight nonmedical use rates and presence of illicit drugs among patients treated with buprenorphine versus full agonist opioids. Important safety and approved-use information for BELBUCA (buprenorphine buccal film) is also included.
Collegium Pharmaceutical (Nasdaq: COLL) and Paris Hilton launched the "Embrace Your Sparkle" campaign on March 3, 2026 to raise awareness and destigmatize ADHD. Paris shares her personal ADHD journey and describes using JORNAY PM—an evening-dosed methylphenidate formulation—to support morning functioning and daytime symptom control.
The campaign promotes discussion with healthcare providers about individualized ADHD treatment plans and directs audiences to jornaypm.com/embrace-your-sparkle for resources.
Collegium (Nasdaq: COLL) will participate in multiple investor conferences the week of March 9–11, 2026 in Miami, FL, including Leerink Partners Global Healthcare, Jefferies Biotech on the Beach, The Citizens Life Sciences Conference, and a Barclays fireside chat on March 11 at 9:00 a.m. ET.
A live webcast of the Barclays fireside chat will be available via the Investors section of the company website and a replay will be archived for 90 days.
Collegium (Nasdaq: COLL) reported strong 2025 results: product revenues $780.6M (+24% YoY) and record quarterly revenues of $205.4M (+13% YoY). Jornay PM reached $148.9M for FY 2025 (+48% YoY) and $45.9M in the quarter (+57% YoY). Adjusted EBITDA was $460.5M (+15% YoY). The company exited 2025 with $386.7M in cash and reaffirmed 2026 guidance: Product Revenues $805–825M; Jornay PM $190–200M; Adjusted EBITDA $455–475M.
Boston Legacy FC announced a multi-year partnership with Collegium Pharmaceutical (NASDAQ: COLL) to sponsor the Collegium Sensory Room. The rooms will be available at Gillette Stadium and Centreville Bank Stadium in 2026 and at White Stadium beginning in 2027.
The sensory rooms, designed with CHADD input, provide quieter, regulated spaces for fans with sensory sensitivities and include branded signage, digital mentions, and community programming.
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Collegium (Nasdaq: COLL) will present four real‑world data posters on its ADHD product Jornay PM at the APSARD Annual Conference, Jan 15–18, 2026, in San Diego.
Poster session: Jan 17, 2026, 11:45 a.m.–12:45 p.m. PT at Manchester Grand Hyatt, Seaport E. Posters (Nos. 73–76) cover dosing, comparative risks/benefits with Concerta, morning/evening functioning in youth, and depression/anxiety outcomes in adults.
Collegium (NASDAQ: COLL) provided 2026 financial guidance and a business update on Jan 8, 2026. The company expects product net revenues of $805M–$825M, Jornay PM net revenue of $190M–$200M, and adjusted EBITDA of $455M–$475M for full-year 2026. Collegium closed a $980M syndicated credit facility in December 2025, used in part to repay $581M of its prior term loan, yielding immediate annualized interest savings. The company also announced an authorized generic supply agreement with Hikma, with planned Nucynta ER AG launch in Q1 2026 and broader AG timing tied to third-party generics.
Collegium (Nasdaq: COLL) closed a five-year, $980 million inaugural syndicated credit facility maturing in 2030. The facility includes a $580M initial term loan, a $300M delayed draw term loan (undrawn at closing), and a $100M revolving credit facility (undrawn at closing).
Collegium used the initial term loan to repay approximately $581M of principal on its prior $646M term loan. Interest is set at SOFR plus 2.75%–3.75% based on first lien net leverage, with the closing rate at SOFR+2.75%. The company expects this refinancing to produce meaningful annualized interest savings and provide capital flexibility for general corporate purposes and business development. Truist Bank acted as administrative agent; a syndicate of banks served as arrangers and agents.